| |  Online-Ressource |
|---|
| Verfasst von: | Lüftner, Diana [VerfasserIn]  |
|---|
| | Schütz, Florian [VerfasserIn] |
|---|
| | Schneeweiss, Andreas [VerfasserIn] |
|---|
| | Hartkopf, Andreas [VerfasserIn] |
|---|
| | Bloch, Wilhelm [VerfasserIn] |
|---|
| | Decker, Thomas [VerfasserIn] |
|---|
| | Uleer, Christoph [VerfasserIn] |
|---|
| | Stötzer, Oliver [VerfasserIn] |
|---|
| | Foerster, Frank [VerfasserIn] |
|---|
| | Schmidt, Marcus [VerfasserIn] |
|---|
| | Mundhenke, Christoph [VerfasserIn] |
|---|
| | Tesch, Hans [VerfasserIn] |
|---|
| | Jackisch, Christian [VerfasserIn] |
|---|
| | Fischer, Thomas [VerfasserIn] |
|---|
| | Kreuzeder, Julia [VerfasserIn] |
|---|
| | Guderian, Gernot [VerfasserIn] |
|---|
| | Fasching, Peter A. [VerfasserIn] |
|---|
| Titel: | Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer |
|---|
| Titelzusatz: | results from the open-label, multicentre, non-interventional BRAWO study |
|---|
| Verf.angabe: | Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, Andreas Hartkopf, Wilhelm Bloch, Thomas Decker, Christoph Uleer, Oliver Stötzer, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Thomas Fischer, Julia Kreuzeder, Gernot Guderian, Peter A. Fasching |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 1 July 2024 |
|---|
| Umfang: | 11 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Zuerst veröffentlicht: 06. März 2024 ; Gesehen am 23.08.2024 |
|---|
| Titel Quelle: | Enthalten in: International journal of cancer |
|---|
| Ort Quelle: | Bognor Regis : Wiley-Liss, 1966 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 155(2024), 1 vom: Juli, Seite 128-138 |
|---|
| ISSN Quelle: | 1097-0215 |
|---|
| Abstract: | BRAWO, a real-world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2- advanced breast cancer (ABC) in routine clinical practice. Postmenopausal women with HR+/HER2-ABC with recurrence or progression after a NSAI were included. Primary Observation parameters included the evaluation of the effectiveness of EVE + EXE. A multivariate-analysis using Cox proportional hazard model was built to identify predictors of progression. Overall, 2100 patients were enrolled (August 2012-December 2017); 2074 were evaluable for efficacy and safety analyses. Majority of patients (60.6%) received EVE + EXE as first (28.7%) or second-line (31.9%) therapy. Visceral metastases were present in 54.1% patients. Median progression-free survival (mPFS) reported as 6.6 months (95%CI: 6.3-7.0). Multivariate-analysis in a subset of patients (n = 1837) found higher body mass index (BMI) and non-visceral metastases to be independent predictors of favorable PFS. Patients with a BMI of 20 to <25 had a mPFS of 6.0 (95%CI: 5.4-6.4) and those with a BMI ≥30 had mPFS of 8.5 (95%CI: 6.9-9.9). 41.2% patients achieved stable disease and 7.3% partial response. No major changes were observed QoL; 86.4% patients received stomatitis prophylaxis and 41.4% experienced EVE related AEs of stomatitis, mainly low grade. AEs occurred in 91.2% of patients, of which stomatitis (42.6%) and fatigue (19.8%) were most frequent. The BRAWO study provides real-world evidence of efficacy and safety of EVE + EXE in patients with HR+, HER2− ABC. A high BMI and the absence of visceral metastases were independent predictors of PFS in this cohort of patients. |
|---|
| DOI: | doi:10.1002/ijc.34912 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1002/ijc.34912 |
|---|
| | Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.34912 |
|---|
| | DOI: https://doi.org/10.1002/ijc.34912 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | advanced breast cancer |
|---|
| | everolimus |
|---|
| | exemestane |
|---|
| | HER2- |
|---|
| | HR+ |
|---|
| K10plus-PPN: | 1899439382 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer / Lüftner, Diana [VerfasserIn]; 1 July 2024 (Online-Ressource)
